AML [clinicaltrials_resource:c043056a0a32cb5e104aeb2cf4ff7ba8]
clinicaltrials:NCT00013533Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia [clinicaltrials:NCT00167167]clinicaltrials:NCT00167180clinicaltrials:NCT00176839clinicaltrials:NCT00176930Stem Cell Transplant With Specially Treated Cells in Treating Patients With Acute Leukemia [clinicaltrials:NCT00246649]Study of Bexarotene in Patients With Acute Myeloid Leukemia [clinicaltrials:NCT00316030]Study of XL999 in Patients With Acute Myeloid Leukemia (AML) [clinicaltrials:NCT00322673]CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation [clinicaltrials:NCT00333190]A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies [clinicaltrials:NCT00405743]clinicaltrials:NCT00422591A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status [clinicaltrials:NCT00462761]Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders [clinicaltrials:NCT00511537]Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies [clinicaltrials:NCT00533078]Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders [clinicaltrials:NCT00533923]clinicaltrials:NCT00539695clinicaltrials:NCT00542971DaunoXome + Ara-C vs Daunorubicin + Ara-C in Elderly AML [clinicaltrials:NCT00589082]Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders [clinicaltrials:NCT00636909]clinicaltrials:NCT00652626Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant [clinicaltrials:NCT00684008]Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML) [clinicaltrials:NCT00684918]Evaluation of Formin Gene Status and Expression in Myeloproliferative and Myelodysplastic Disorders [clinicaltrials:NCT00687414]Treatment Outcome in Elderly Patients [clinicaltrials:NCT00700544]High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML) [clinicaltrials:NCT00707408]Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML) [clinicaltrials:NCT00744081]clinicaltrials:NCT00761449Sirolimus in Combination With MEC in High Risk Myeloid Leukemias [clinicaltrials:NCT00780104]clinicaltrials:NCT00780598clinicaltrials:NCT00808080Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI) [clinicaltrials:NCT00815568]Induction With or Without Granulocyte Colony-Stimulating Factor in AML Transplantation in AML [clinicaltrials:NCT00820976]STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders [clinicaltrials:NCT00858572]Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL) [clinicaltrials:NCT00863148]clinicaltrials:NCT00887068Umbilical Cord Blood Transplant for Hematological Malignancies [clinicaltrials:NCT00891592]A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia [clinicaltrials:NCT00964873]clinicaltrials:NCT01012492clinicaltrials:NCT01019317Phase I Study in RAD 001 Patients With Relapse AML [clinicaltrials:NCT01074086]
condition [clinicaltrials_vocabulary:condition]
eligibility for clinicaltrials:NCT00544466 [clinicaltrials_resource:17eda8d4fb5b423a4ae0eb016206e589]eligibility for clinicaltrials:NCT02305563 [clinicaltrials_resource:4e0f1bc6f2c3904bc941ea03d278d439]eligibility for clinicaltrials:NCT00202917 [clinicaltrials_resource:540656d8a1a623283bf3a0504337ec79]eligibility for clinicaltrials:NCT00324220 [clinicaltrials_resource:63595feb3b0228bcab5f54af1cd0ce62]eligibility for clinicaltrials:NCT00392353 [clinicaltrials_resource:9431056fcd5e22d481af8f60e5f1916b]eligibility for clinicaltrials:NCT00972101 [clinicaltrials_resource:b424afb4b8a211a13f358ec140e1f8bb]eligibility for clinicaltrials:NCT00710528 [clinicaltrials_resource:c83f2a9f3f67cf9491f8173ffbd8357e]
exclusion criteria [clinicaltrials_vocabulary:exclusion-criteria]
eligibility for clinicaltrials:NCT00544466 [clinicaltrials_resource:17eda8d4fb5b423a4ae0eb016206e589]eligibility for clinicaltrials:NCT02305563 [clinicaltrials_resource:4e0f1bc6f2c3904bc941ea03d278d439]eligibility for clinicaltrials:NCT00202917 [clinicaltrials_resource:540656d8a1a623283bf3a0504337ec79]eligibility for clinicaltrials:NCT00324220 [clinicaltrials_resource:63595feb3b0228bcab5f54af1cd0ce62]eligibility for clinicaltrials:NCT00392353 [clinicaltrials_resource:9431056fcd5e22d481af8f60e5f1916b]eligibility for clinicaltrials:NCT00972101 [clinicaltrials_resource:b424afb4b8a211a13f358ec140e1f8bb]eligibility for clinicaltrials:NCT00710528 [clinicaltrials_resource:c83f2a9f3f67cf9491f8173ffbd8357e]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
AML [clinicaltrials_resource:c043056a0a32cb5e104aeb2cf4ff7ba8]
Bio2RDF identifier
c043056a0a32cb5e104aeb2cf4ff7ba8
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:c043056a0a32cb5e104aeb2cf4ff7ba8
identifier
clinicaltrials_resource:c043056a0a32cb5e104aeb2cf4ff7ba8
title
AML
@en
type
label
AML [clinicaltrials_resource:c043056a0a32cb5e104aeb2cf4ff7ba8]
@en